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Introduction: Exon 20 insertions are the third most common fam-
ily of epidermal growth factor receptor (EGFR) mutations found in 
non–small-cell lung cancer (NSCLC). Little is known about cancers 
harboring these mutations aside from their lack of response to EGFR 
tyrosine kinase inhibitors, impairing the development of effective 
targeted therapies.
Methods: NSCLC patients with EGFR genotyping were studied 
using a mechanism approved by the Institutional Review Board. 
Cancers with exon 20 insertions were indentified, sequences were 
characterized, and effectiveness of different treatment regimens was 
reviewed retrospectively. Clinical characteristics and survival were 
compared with cancers harboring common EGFR mutations and 
cancers with wild-type EGFR.
Results: One thousand eighty-six patients underwent EGFR geno-
typing from 2004 to 2012. Twenty seven (2.5%) harbored exon 20 
insertions, making up 9.2% of all cancers with documented EGFR 
mutations. Compared with wild-type cancers, those with exon 20 
insertions were more commonly found in never-smokers and Asian 
patients. Insertion sequences were highly variable, with the most 
common variant (V769_D770insASV) making up only 22% of 
cases. Median survival of patients with exon 20 insertions was 16 
months, similar to the survival of wild-type cancers and shorter than 
the survival of cancers with common EGFR mutations.
Conclusions: Patients with EGFR exon 20 insertions have similar 
clinical characteristics to those with common EGFR mutations but a 
poorer prognosis. The prevalence of this subset of NSCLC is similar 
to that of other genotype-defined subsets of lung adenocarcinoma (e.g. 
those with BRAF mutations, HER2 insertions, ROS1 rearrangements) 
and is a population of interest for trials of new targeted therapies.
Key Words: Non–small-cell lung cancer, Epidermal growth factor 
receptor mutations, Exon 20 insertions.
(J Thorac Oncol. 2013;8: 179–184)
The identification of epidermal growth factor receptor (EGFR) mutations in a subset of non–small-cell lung can-
cer (NSCLC) and their association with durable responses to 
EGFR tyrosine kinase inhibitors (TKIs) has transformed our 
approach towards the use of targeted therapies in treating lung 
cancer.1,2 This initial discovery has led to a number of paral-
lel discoveries—lung adenocarcinomas harboring ALK and 
ROS1 rearrangements are both highly sensitive to critozinib,3,4 
while melanomas harboring BRAF V600 mutations are highly 
sensitivity to BRAF and MEK inhibitors.5,6 These therapeutic 
advances have led to numerous efforts to identify genotype-
defined subsets of common cancers which can be treated with 
rationally targeted therapies.
Lung cancers harboring exon 20 insertions in EGFR 
make up one genotype-defined subset of lung cancer that is 
in need of an effective targeted treatment approach. These 
were one of the earliest described families of EGFR muta-
tions, identified contemporaneously with the common (and 
better studied) TKI-sensitive mutations in exon 19 and 21 of 
EGFR.7,8 Unlike EGFR exon 19 deletions and exon 21 point 
mutations, exon 20 insertions are not associated with sensi-
tivity to EGFR TKIs in laboratory studies and in clinical tri-
als,9–11 though these insertion mutations have been shown to 
be oncogenic when transfected into cell lines.11 Additionally, a 
family of exon 20 insertions has been described in the HER2 
gene,12,13 which encodes a membrane-bound kinase with sig-
nificant homology to EGFR, highlighting the potential bio-
logical importance of insertion mutations in this part of the 
kinase domain. Though exon 20 insertions are the third most 
common family of EGFR mutations and have been identified 
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on routine EGFR genotyping for many years, no prospective 
studies to our knowledge have specifically targeted this sub-
set of NSCLC, and lung cancers harboring exon 20 insertions 
have been excluded from many prospective trials of EGFR 
inhibitors because of the reports of resistance to EGFR TKIs.
To facilitate drug development for this genotype- 
defined subset of NSCLC, we aimed to characterize our single-
center experience of patients with lung cancers carrying 
EGFR exon 20 insertions. We hypothesized that, despite 
the presence of EGFR mutations, the clinical outcomes of 
lung cancers harboring EGFR exon 20 insertions would be 
similar to EGFR wild-type cancers, supporting the need 
for effective targeted therapy options for this subset of lung 
cancer.
MATERIALS AND METHODS
Patients for this study were identified from two cohorts: 
a prospective cohort of lung cancer patients who consented 
to an institutional tissue analysis protocol, and a retrospective 
cohort of lung cancer patients whose records were reviewed 
and studied with Institutional Review Board approval. Of 
these patients, subjects were deemed eligible for study if they 
had a diagnosis of NSCLC and had undergone conclusive 
EGFR genotyping. Patients were grouped into four popu-
lations based upon the EGFR genotype of their cancer: (1) 
EGFR exon 20 insertions, (2) common TKI-sensitive EGFR 
mutations (exon 19 deletions or L858R point mutations), (3) 
other rare EGFR mutations, and (4) EGFR wild-type. Those 
patients with a result of “EGFR mutation positive” but with 
no additional sequence details available were excluded from 
the analysis.
EGFR genotyping for this study was performed at the 
Laboratory for Molecular Medicine at Harvard University. 
Specimens deemed to have adequate tumor content were sub-
mitted for extraction of somatic DNA, and underwent direct 
Sanger sequencing of exons 18 through 21 of EGFR as previ-
ously described.14 EGFR genotyping performed at a separate 
CLIA-approved laboratory was also deemed adequate for this 
analysis, therefore was not repeated at the central laboratory. 
The amino-acid sequences of the identified exon 20 insertions 
were characterized and compared.
Patient characteristics at time of lung cancer diagno-
sis were prospectively collected, including age, sex, race, 
smoking history (never-smoker was defined as less than 100 
cigarettes in life time), stage (per AJCC VII), and histologic 
classification. For patients with advanced disease (stage IV or 
recurrent), survival was calculated from date of diagnosis (for 
stage IV) or from date of recurrence (for stage I-III) until the 
date of death from any cause, as in other analyses.15 Patients 
who were alive at the time of analysis were censored at the last 
known date of follow-up.
The systemic treatment of advanced lung cancers har-
boring EGFR exon 20 insertions was reviewed to characterize 
its effectiveness. Because of the small sample size, patients 
receiving multiple lines of treatment could be considered up 
to three times, in each of three different treatment settings, 
but were not studied more than once within a given treatment 
setting. The first treatment setting included patients receiving 
erlotinib as a single agent, regardless of line of therapy. The 
second treatment setting included patients receiving plati-
num-based combination chemotherapy, regardless of whether 
this was before erlotinib (considered first-line) or after erlo-
tinib (considered second-line). The third treatment setting 
included patients receiving subsequent single-agent cytotoxic 
chemotherapy, after failure of combination chemotherapy. 
Combinations of these treatments (e.g., erlotinib plus chemo-
therapy), investigational treatments, and treatments given in 
the setting of no evaluable disease (e.g., adjuvant therapies) or 
without any follow-up imaging were excluded from the anal-
ysis. Time to treatment failure (TTF) was determined retro-
spectively from review of records, and was defined as the time 
from the start of each therapy until a change of treatment regi-
men. For those with serial CT imaging available during ther-
apy and measurable disease, maximal tumor shrinkage was 
determined by blinded radiology review. Objective response 
rate was calculated using Response Evaluation Criteria in 
Solid Tumors (RECIST) version 1.1 criteria,16 but response 
confirmation was not required because of the retrospective 
nature of the study. Because some patients were studied multi-
ple times in different treatment settings, no statistical analysis 
was performed comparing each treatment setting.
Categorical data were compared using the Fisher’s exact 
test, and continuous data were compared using the Wilcoxon 
rank sum test. The Kaplan-Meier method was used to estimate 
the overall survival distributions, and the Greenwood formula 
was used to estimate the variance. Time-to-event distribu-
tions were compared using the log-rank test. All p values are 
two-sided, and no adjustments have been made for multiple 
comparisons.
RESULTS
A total of 1086 patients had conclusive EGFR genotyp-
ing from 2004 to 2012: 29% were never-smokers, 63% were 
women, 6% were Asian, and 99% had nonsquamous histol-
ogy (Table 1). Of the total, 294 (27%) harbored EGFR muta-
tions; 27 of these (2.5%) harbored EGFR exon 20 insertions, 
constituting 9.2% of all cases with an EGFR mutation. Other 
genotypes included 128 cancers with exon 19 deletions, 101 
cancers with L858R point mutations, and 38 cancers harbor-
ing other rare EGFR mutations.
The characteristics of cancers with EGFR exon 20 
insertions are shown in Table 1, along with the clinical charac-
teristics of cancers that carried common EGFR mutations and 
those that were EGFR wild-type. No significant differences 
were identified between the cancers carrying exon 20 inser-
tions and those with the common EGFR mutations. However, 
cancers with exon 20 insertions were more commonly seen 
in patients who are never-smokers (p < 0.001) and in patients 
of an Asian race (p = 0.02) when compared with EGFR wild-
type cancers, similar to the patients with the common EGFR 
mutations. There was a trend toward an increased proportion 
of cancers with exon 20 insertions being stage IV at diagnosis 
(p = 0.05); this may in part be owing to referral bias because 
our cancer center has a research program focusing on treat-
ments for advanced EGFR-mutant lung cancers.
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The amino acid sequences of the 27 EGFR exon 20 
insertions included 13 different variants occurring at seven 
different amino acid positions (Table 2). Review of the 
amino acid sequences revealed a large degree of variability 
in insertion length (1, 2, 3, or 4 residues), insertion sequence, 
and insertion position. Only eight of the 13 variants occurred 
more than once. To contextualize the variety of EGFR exon 20 
insertions identified, we considered the variety of insertions 
in EGFR exon 19 and in HER2 exon 20 from the two largest 
published series on these families of mutations (Fig. 1).13,17 
The most common variants of EGFR exon 19 insertions and 





















Residue number:  760  765  770  775
*Insertions sequences are registered around the uninvolved residues Y764-V769 





EGFR Mutations Exon 20 Insertions EGFR Wild-Type
n =1086 % n = 229 % p* n = 27 % p** n = 792 %
Age
 Median 62 60 0.65 60 0.23 62
 Range (yrs) 20–95 30–95 25–80 20–88
Smoking status
 Never 313 29% 120 52% 0.84 15 56% <0.001 161 20%
 Ever 773 71% 109 48% 12 44% 631 80%
Sex:
 Women 679 63% 168 73% 0.82 19 70% 0.24 462 58%
 Men 407 37% 61 27% 8 30% 330 42%
Race
 Asian 62 6% 25 11% 0.52 4 15% 0.02 30 4%
 Non-Asian 1024 94% 204 89% 23 85% 762 96%
Stage
 IV 579 53% 133 58% 0.3 19 70% 0.05 401 51%
 I-III 507 47% 96 42% 8 30% 391 49%
Histology
 Nonsquamous 1071 99% 226 99% 1 27 100% 1 780 98%
 Squamous 15 1% 3 1% 0 0% 12 2%
*Comparison of common EGFR mutations and exon 20 insertions.
**Comparison of EGFR wild-type cancers and exon 20 insertions.
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but the most common variant of EGFR exon 20 insertions 
(V769_D770insASV) constitutes only 22% of the total cohort. 
Table 2 shows the sequence of each variant, registered around 
residues Y764 through V769, a section that spans the terminus 
of the C-helix (at M766) and is uninvolved by any insertions. 
Reviewing these sequences, there are few trends and few 
recurring substitutions at any specific position. For example, 
while the most common variant shares the insertion of a serine 
and valine at positions 771 and 772 with D770_N771insSVD, 
no other insertion variants include a serine residue.
Nineteen patients with EGFR exon 20 insertions 
received treatment for advanced disease, with a total of 34 
different treatment courses studied (Fig. 2). Eight patients 
received erlotinib, with a median TTF of 2.4 months (range, 
1.0–4.5 months); of five patients with imaging available, 
none demonstrated an objective response. Seventeen patients 
received combination chemotherapy with a median TTF of 5.9 
months (range, 1.3–17.7 months); of 12 patients with imag-
ing available, seven demonstrated an objective response. Nine 
patients received subsequent cytotoxic chemotherapy with a 
median TTF of 2.3 months (range, 1.2–7.0 months); of six 
patients with imaging available, one demonstrated an objec-
tive response.
Survival analysis was performed on the 839 patients 
with advanced disease (553 stage IV at diagnosis and 286 
recurrent), with a median follow-up of 30 months. The 24 
patients with advanced lung cancers harboring EGFR exon 20 
insertions had a median survival of 16.5 months (95% con-
fidence interval [CI]: 10.4–NA) from date of advanced dis-
ease. Their survival was shorter than that of the 183 patients 
with common EGFR mutations (median 33.0 months, 95% CI 
28.7–40.6, p = 0.06, Fig. 3A), but was not dissimilar from the 
survival of the 632 patients with EGFR wild-type lung cancers 
(median 20.0 months, 17.4–22.9, p = 0.60, Fig. 3B).
DISCUSSION
We have identified that lung cancers harboring EGFR 
exon 20 insertions exhibit clinical characteristics similar to 
lung cancers carrying common EGFR mutations, with a ten-
dency to occur in never-smokers and Asian patients. This is 
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with the potential for durable benefit from an effective tar-
geted therapy. However, patients with this family of muta-
tions have a survival similar to that seen in EGFR wild-type 
lung cancers. While patients with advanced lung cancers car-
rying TKI-sensitive EGFR mutations had a median survival 
of 33.0 months, similar to reports from other academic cen-
ters,18 patients with cancers carrying exon 20 insertions had a 
median survival of only 16.5 months. It should be noted that, 
while these medians are longer than those seen in first-line 
treatment studies, they are similar to those seen in other analy-
ses measuring survival from date of advanced disease.15
Our finding that 9.2% of EGFR-mutant lung cancers 
harbor exon 20 insertions is somewhat higher than the 4% to 
5% prevalence found by some prior analyses.10,19,20 While this 
higher prevalence may reflect referral bias, it is also expected 
that the prevalence of these mutations will vary depending 
upon which genotyping technique is used. Sanger sequenc-
ing, used in this analysis and in many commercial labs, is 
able to detect all varieties of insertion mutations. In contrast, 
mutation-specific assays such as the EGFR PCR kit by Qiagen 
(Valencia, CA) includes only three exon 20 insertion variants 
among the specific EGFR mutations that it tests for, such that 
it would have detected fewer than half of the cases with exon 
20 insertions in our series. Going forward, efforts to study this 
subset of lung cancer will need to use genotyping assays that 
are not mutation-specific, or else a portion of these cancers 
might be missed.
Given our prevalence findings, we estimate that lung 
cancers with EGFR exon 20 have an annual incidence of 
approximately 2000 to 4000 patients in the United States, 
not dissimilar from the expected incidence of other uncom-
mon genotype-defined subsets of NSCLC such as those with 
ROS1 rearrangements, BRAF mutations, or HER2 inser-
tions.4,13,21 While detection of ROS1 rearrangements currently 
requires an independent break-apart FISH assay, exon 20 
insertions can be routinely detected during standard-of-care 
EGFR genotyping. Because patients with this genotype will 
continue to emerge during standard-of-care EGFR genotyp-
ing, we encourage other investigators to develop trials for 
lung cancers with EGFR exon 20 insertions, towards the goal 
of potentially developing an orphan drug for this genotype-
defined rare disease.22 One treatment strategy that has shown 
preliminary efficacy in EGFR-mutant lung cancers that are 
resistant to TKI is HSP90 inhibition, with responses seen in 
preclinical models as well as in some patients.23–25 A clinical 
trial in development is studying the HSP90 inhibitor AUY922 
in lung cancers harboring EGFR exon 20 insertions, which 
would be first prospective trial specifically targeting this gen-
otype-defined subset of NSCLC. Alternatively, new kinase 
inhibitors may need to be developed against this specific fam-
ily of kinase mutations, or developed jointly for HER2 inser-
tion mutations. To facilitate these efforts, a transgenic mouse 
model of NSCLC carrying a HER2 exon 20 insertion has 
been generated by our colleagues,26 and a model harboring an 
EGFR exon 20 insertion is in development.
The highly variable length and position of EGFR exon 
20 insertions contrasts with the more consistent insertions 
seen in exon 19 of EGFR and in exon 20 of HER2.13,17 
Looking at the sequences of the insertions (Table 2), there 
is no consistent substitution seen that is shared by the entire 
spectrum. This contrasts with deletions and insertions in 
exon 19 of EGFR, which commonly involve a substitution at 
L747 to either a proline or a serine, a substitution that may 
underlie the oncogenicity of these types of mutations by 
disfavoring the inactive conformation of the mutant EGFR 
kinase.17 Supporting the importance of this residue, exon 19 
deletions that do not include a substitution at 747 have been 
found to have poorer outcomes when treated with TKI.27 The 
lack of structural consistency among the exon 20 insertions 
may indicate a particularly varied biology among this family 
of mutations. Indeed, cell line studies have recently indicated 
that one variant of exon 20 insertions, A763_Y764insFQEA, 
is actually sensitive to treatment with erlotinib.28 In our cohort, 
only one patient harboring this insertion variant was treated 
with erlotinib, and objective response assessment identified 
stable disease lasting 4 months. Given that our understanding 
of the biology of these mutations is still evolving, it would be 
valuable if, when radiographic responses are seen to EGFR 
TKI in lung cancers with EGFR exon 20 insertions, they be 
reported with mention of the specific sequence of the insertion 
variant.29 For example, the one published report of response 
to an irreversible TKI also involved a rare exon 20 insertion 
variant, D770delinsGY, which may suggest distinct biologic 
characteristics.30
Our retrospective analysis of treatment effectiveness 
was limited in its ability to evaluate different treatment 
approaches because of the small number of lung cancers 
harboring exon 20 insertions. However, by considering each 
patient multiple times when treated in different treatment set-
tings, we were able to generate an initial sense of how some 
therapies work in this subset of cancers. Combination chemo-
therapy resulted in a sizeable proportion of patients having 
objective responses with a median TTF of 5.9 months; this is 
consistent with the results seen when treating advanced lung 
adenocarcinoma in general. Subsequent chemotherapy was 
relatively less effective, as was erlotinib, suggesting that pre-
viously treated NSCLC carrying EGFR exon 20 insertions 
may be an appropriate setting for the development of new 
therapies. Though such analyses are merely descriptive and 
based upon retrospective data, we hope that presenting them 
in the medical literature may facilitate later efforts for drug 
development.
In conclusion, we have found that lung cancers harbor-
ing EGFR exon 20 insertions have the clinical characteristics 
of other lung cancers carrying targetable oncogenes and are 
just as prevalent, but exon 20 insertions are associated with a 
poorer survival than common TKI-sensitive EGFR mutations. 
Previously treated NSCLC carrying EGFR exon 20 insertions 
represent a population of oncogene-addicted cancers in need 
of targeted therapy development.
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